Efficacy of Inulin Supplementation in Improving Insulin Control, HbA1c and HOMAAIR in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials

DOI Web Site 被引用文献2件 参考文献56件
  • Zhang Wenyue
    Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University Department of Clinical Nutrition, The Second Affiliated Hospital of Chongqing Medical University
  • Tang Yao
    Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University
  • Huang Juan
    Department of Clinical Nutrition, The Second Affiliated Hospital of Chongqing Medical University
  • Yang Yixuan
    Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Institute for Viral Hepatitis, The Second Affiliated Hospital of Chongqing Medical University
  • Yang Qinbing
    Department of Clinical Nutrition, Beijing Tsinghua Changgung Hospital Medical Center, Tsinghua University
  • Hu Huaidong
    Department of Clinical Nutrition, The Second Affiliated Hospital of Chongqing Medical University

書誌事項

タイトル別名
  • Efficacy of inulin supplementation in improving insulin control, HbA1c and HOMA-IR in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
公開日
2020
DOI
  • 10.3164/jcbn.19-103
公開者
一般社団法人　日本酸化ストレス学会

この論文をさがす

説明

<p>Type 2 diabetes mellitus is a chronic disease that occurs among the general population. The insulin-lowering and homeostasis model assessment of insulin resistance-improving effects of inulin are unconfirmed. We conducted this meta-analysis to examine the efficiency and safety of inulin for improving insulin control, homeostasis model assessment of insulin resistance and HbA1c in patients with type 2 diabetes mellitus. We searched the Web of Science, PubMed, Embase and Cochrane Library databases for relevant articles published before June 1, 2019. In total, 225 randomized controlled trials regarding the efficiency of inulin for the treatment of type 2 diabetes mellitus compared to the efficacy of placebo or other treatments were examined. According to the inclusion and exclusion criteria, 9 trials with a total of 661 participants were included. We concluded that inulin supplementation can significantly improve fasting plasma glucose (SMD = −0.55, 95% CI –0.73 to −0.36, p = 0), HOMA-IR (SMD = −0.81, 95% CI –1.59 to −0.03, p = 0.042) and HbA1c (SMD = −0.69, 95% CI −0.92 to −0.46, p = 0). Further subgroup analyses revealed a significant role of inulin supplementation for treatment durations ≥8 weeks (p = 0.038 for insulin, p = 0.002 for HOMA-IR, p = 0.032 for FPG, p = 0 for HbA1c).</p>

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (56)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ